Crestani, Bruno

Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline

Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 2,957

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., CORIMUNO-19 Collaborative Group, Bureau, S., Dougados, M., Tibi, A., et al. (2021) · JAMA Internal Medicine

COVID-19 Clinical Research StudiesRespiratory Support and Mechanisms

Cited by 734

Extracellular ATP Is a Danger Signal Activating P2X7 Receptor in Lung Inflammation and Fibrosis

Riteau, N., Gasse, P., Fauconnier, L., Gombault, A., Couegnat, M., Fick, L., Kanellopoulos, J., Quesniaux, V. F. J., Marchand-Adam, S., Crestani, B., et al. (2010) · American Journal of Respiratory and Critical Care Medicine

Adenosine and Purinergic SignalingInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 397

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Guenther, A., Krauss, E., Tello, S., Wagner, J., Paul, B., Kuhn, S., Maurer, O., Heinemann, S., Costabel, U., Barbero, M. A. N., et al. (2018) · Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 268

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials

Lancaster, L., Crestani, B., Hernandez, P., Inoue, Y., Wachtlin, D., Loaiza, L., Quaresma, M., Stowasser, S., & Richeldi, L. (2019) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 209

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 150

Internalization of Aspergillus fumigatus conidia by epithelial and endothelial cells

Paris, S., Boisvieux-Ulrich, E., Crestani, B., Houcine, O., Taramelli, D., Lombardi, L., & Latgé, J. P. (1997) · Infection and Immunity

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 149

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 148

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Behr, J., Bendstrup, E., Crestani, B., Günther, A., Olschewski, H., Sköld, C. M., Wells, A., Wuyts, W., Koschel, D., Kreuter, M., et al. (2016) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 146

Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis

Taillé, C., Grootenboer-Mignot, S., Boursier, C., Michel, L., Debray, M.-P., Fagart, J., Barrientos, L., Mailleux, A., Cigna, N., Tubach, F., et al. (2011) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 120

B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis

François, A., Gombault, A., Villeret, B., Alsaleh, G., Fanny, M., Gasse, P., Adam, S. M., Crestani, B., Sibilia, J., Schneider, P., et al. (2015) · Journal of Autoimmunity

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTransplantation: Methods and Outcomes

Cited by 109

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

Kolb, M., Crestani, B., & Maher, T. M. (2023) · European Respiratory Review

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation

Cited by 85

Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis

Taı̈eb, J., Delarche, C., Paradis, V., Mathurin, P., Grenier, A., Crestani, B., Dehoux, M., Thabut, D., Gougerot-Pocidalo, M.-A., Poynard, T., et al. (2002) · Journal of Hepatology

Liver physiology and pathologyAlcohol Consumption and Health Effects

Cited by 73

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON

Song, J. W., Ogura, T., Inoue, Y., Xu, Z., Quaresma, M., Stowasser, S., Stansen, W., & Crestani, B. (2020) · Respirology

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 39